Roman Ivanov

Russian Revolution for Biosimilars

Biologics are expensive, but so too are biosimilars. Could local manufacturers based in Russia and other emerging markets, with their inherently lower costs, be well placed to develop cheaper biopharmaceuticals to benefit public health?